Literature DB >> 3129668

Intramedullary spinal cord tumors resected with CO2 laser microsurgical technique: recent experience in fifteen patients.

H D Herrmann1, M Neuss, D Winkler.   

Abstract

We have operated upon 15 intramedullary spinal cord tumors with the aid of a CO2 laser attached to the microscope. The operative technique is described. Most of the tumors were localized within the cervical spinal cord. Nine tumors were benign gliomas: 4 ependymomas, 1 subependymoma, 3 astrocytomas, and 1 ganglioglioma. Six were removed totally, and 3 were removed subtotally. The remaining 6 tumors consisted of 3 hemangioblastomas, 1 intramedullary neurofibroma, 1 lipoma, and 1 primary intramedullary melanoma. Neurological function postoperatively compared to the preoperative function of the upper extremities was unchanged in 13 patients (86.5%), improved in 1, and worse in 1 patient. In the lower extremities, the preoperative neurological status was unchanged in 11 patients (73.3%), improved in 1 patient, and worse in 3 patients (20%). Magnetic resonance imaging was superior to myelography and computed tomography in localizing these lesions. Enhancement with paramagnetic substances (e.g., gadolinium-DTPA) helps to localize solid tumor within cysts. Histological evaluation of small tissue biopsies or frozen section histology is unreliable. The entire lesion should be exposed in all cases, and an attempt should be made to remove the tumor totally or, if this is not possible, to resect as much of the center of the tumor as is possible until the cord is decompressed. The decision to administer further treatment is based on the histological features of the tumor.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3129668     DOI: 10.1227/00006123-198803000-00011

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  14 in total

Review 1.  Intraparenchymal schwannomas of the central nervous system: an additional case report and review.

Authors:  E Beşkonakli; S Cayli; M Turgut; U Bostanci; S Seçkin; Y Yalçinlar
Journal:  Neurosurg Rev       Date:  1997       Impact factor: 3.042

2.  Spinal cord ganglioglioma presenting as hydrocephalus.

Authors:  G Miller; J Towfighi; R B Page
Journal:  J Neurooncol       Date:  1990-10       Impact factor: 4.130

3.  Surgical treatment of hemangioblastomas of the central nervous system in pediatric patients.

Authors:  Vassilios I Vougioukas; Sven Gläsker; Ulrich Hubbe; Ansgar Berlis; Heymut Omran; Hartmut P H Neumann; Vera Van Velthoven
Journal:  Childs Nerv Syst       Date:  2005-12-21       Impact factor: 1.475

4.  Surgery of intramedullary spinal cord tumors.

Authors:  M Zileli; E Coşkun; N Ozdamar; I Ovül; E Tunçbay; K Oner; N Oktar
Journal:  Eur Spine J       Date:  1996       Impact factor: 3.134

Review 5.  Central nervous system manifestations in VHL: genetics, pathology and clinical phenotypic features.

Authors:  Sven Gläsker
Journal:  Fam Cancer       Date:  2005       Impact factor: 2.375

6.  External beam radiotherapy for primary spinal cord tumors.

Authors:  H C Chun; R K Schmidt-Ullrich; A Wolfson; O F Tercilla; R H Sagerman; G A King
Journal:  J Neurooncol       Date:  1990-12       Impact factor: 4.130

Review 7.  Hemangioblastomas and other uncommon intramedullary tumors.

Authors:  D J Miller; I E McCutcheon
Journal:  J Neurooncol       Date:  2000-05       Impact factor: 4.130

8.  Surgical treatment of intramedullary tumors (spinal cord and medulla oblongata). Analysis of 16 cases.

Authors:  A Ahyai; U Woerner; E Markakis
Journal:  Neurosurg Rev       Date:  1990       Impact factor: 3.042

9.  Intramedullary vascular lesions in the high cervical region: transoral and dorsal surgical approach. Two case reports.

Authors:  H Friedrich; G Hänsel-Friedrich; H Zeumer
Journal:  Neurosurg Rev       Date:  1990       Impact factor: 3.042

Review 10.  Gangliogliomas: a clinicopathological study of 25 cases and review of the literature.

Authors:  H G Krouwer; R L Davis; M W McDermott; T Hoshino; M D Prados
Journal:  J Neurooncol       Date:  1993-08       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.